Cargando…

Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria

Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is g...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohde, Christine, Wittmann, Johannes, Kutter, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302670/
https://www.ncbi.nlm.nih.gov/pubmed/30256176
http://dx.doi.org/10.1089/sur.2018.184
_version_ 1783382030848884736
author Rohde, Christine
Wittmann, Johannes
Kutter, Elizabeth
author_facet Rohde, Christine
Wittmann, Johannes
Kutter, Elizabeth
author_sort Rohde, Christine
collection PubMed
description Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is gaining momentum because phages represent a therapy concept without such negative side effects as toxicity; phages are the only therapeutic agent that regulates itself at the sites of infection and decays when the infectious bacteria have been killed. Nature is an almost infinite phage resource: New ones can be isolated for most kinds of problem bacteria as needed; bacteria and their phages constantly co-evolve. This is important as new pathogenic bacterial variants evolve and new challenging situations arise. In human therapy, “cocktails” of multiple phages may reduce the probability of selecting bacteria that developed resistance to a certain phage. Antibiotic agents can be applied together with phages in many circumstances; the two often function synergistically. Phages cannot be expected to replace antibiotic agents in our medical arsenal, but can be used where antibiotic agents fail. The selected phages, however, must be obligately virulent, well-characterized, and highly purified before application. Countless patients and their physicians are waiting for re-establishing phage therapy as a flexible, tailored medicine; infrastructures should be built in all countries urgently: The 2015 World Health Organization assembly resolution 68.7.3. called for national action plans by May 2017 to combat the antimicrobial drug resistance crisis. This article discusses the therapeutic potential of phages and describes challenges and recent developments.
format Online
Article
Text
id pubmed-6302670
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-63026702018-12-26 Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria Rohde, Christine Wittmann, Johannes Kutter, Elizabeth Surg Infect (Larchmt) Invited Reviews Bacteriophages (phages) are viruses that kill bacteria specifically but cannot infect other kinds of organisms. They have attracted new attention since the increasing antibiotic resistance developed into a global crisis. Phage therapy, a 100-year-old form of antibacterial treatment in medicine, is gaining momentum because phages represent a therapy concept without such negative side effects as toxicity; phages are the only therapeutic agent that regulates itself at the sites of infection and decays when the infectious bacteria have been killed. Nature is an almost infinite phage resource: New ones can be isolated for most kinds of problem bacteria as needed; bacteria and their phages constantly co-evolve. This is important as new pathogenic bacterial variants evolve and new challenging situations arise. In human therapy, “cocktails” of multiple phages may reduce the probability of selecting bacteria that developed resistance to a certain phage. Antibiotic agents can be applied together with phages in many circumstances; the two often function synergistically. Phages cannot be expected to replace antibiotic agents in our medical arsenal, but can be used where antibiotic agents fail. The selected phages, however, must be obligately virulent, well-characterized, and highly purified before application. Countless patients and their physicians are waiting for re-establishing phage therapy as a flexible, tailored medicine; infrastructures should be built in all countries urgently: The 2015 World Health Organization assembly resolution 68.7.3. called for national action plans by May 2017 to combat the antimicrobial drug resistance crisis. This article discusses the therapeutic potential of phages and describes challenges and recent developments. Mary Ann Liebert, Inc., publishers 2018-11-01 2018-12-05 /pmc/articles/PMC6302670/ /pubmed/30256176 http://dx.doi.org/10.1089/sur.2018.184 Text en © Christine Rohde et al., 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Invited Reviews
Rohde, Christine
Wittmann, Johannes
Kutter, Elizabeth
Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title_full Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title_fullStr Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title_full_unstemmed Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title_short Bacteriophages: A Therapy Concept against Multi-Drug–Resistant Bacteria
title_sort bacteriophages: a therapy concept against multi-drug–resistant bacteria
topic Invited Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302670/
https://www.ncbi.nlm.nih.gov/pubmed/30256176
http://dx.doi.org/10.1089/sur.2018.184
work_keys_str_mv AT rohdechristine bacteriophagesatherapyconceptagainstmultidrugresistantbacteria
AT wittmannjohannes bacteriophagesatherapyconceptagainstmultidrugresistantbacteria
AT kutterelizabeth bacteriophagesatherapyconceptagainstmultidrugresistantbacteria